Skip to main content
Premium Trial:

Request an Annual Quote

Warnex Licenses Rights to Cancer Dx Technology from Epigenomics

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Warnex has licensed from German molecular diagnostics firm Epigenomics non-exclusive rights to the Septin9 biomarker, the firms said in a joint announcement today.

Laval, Quebec-based Warnex intends to create a laboratory-developed test for colorectal cancer incorporating the Septin9 biomarker. It plans to launch a testing service within the next few months, and it expects to be the first provider in Canada of Septin9 testing — with a "time-limited head start period of exclusivity for the Canadian market."

Epigenomics will receive undisclosed royalty payments from Warnex. The firms did not disclose further terms of the agreement.

"This agreement is an important further step in the international rollout of Septin9 testing, which is already commercially available in the US and Europe," Geert Nygaard, CEO of Epigenomics, said in a statement.

Berlin-based Epigenomics sells the CE-marked test Epi proColon, which it said is the world's first regulatory cleared molecular diagnostic test for the detection of colorectal cancer in blood that is based on the Septin9 biomarker.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.